The cyclins and their catalytic partners, the Cyclin Dependent Kinases (CDKs), are essential for progression through the cell cycle. Cyclin/kinase complexes containing cyclins A or E are active primarily in late G 1 to S phase and both have been shown to phosphorylate histone H1 and the retinoblastoma gene product (pRb) in vitro. Despite these similarities, cyclins A and E display dierences in CDK activation and substrate speci®city. We ®nd that in vitro, cyclin E/CDK2 and cyclin A/ CDK2 phosphorylate histone H1 similarly but only cyclin A/CDK2 phosphorylates lamin B. While both cyclin A and cyclin E bind CDK1 eciently, only cyclin A activates CDK1 kinase activity. Using chimeric proteins between cyclins A and E we ®nd that both the cyclin box and C-terminus of cyclins A and E are required for CDK binding, activation and targeting of substrate speci®city.
Introduction
Cell cycle transitions in mammalian cells are regulated by complex pathways involving multiple cell cycle kinases (CDKs) and kinase regulatory proteins (cyclins). Early studies on CDKs using yeast as a model system demonstrated that two important checkpoints in the cell cycle, entry into S phase and mitosis, were controlled by the cdc2/CDC28 kinase (hereafter called CDK1, reviewed in (Naysmith, 1993) . CDK1 is also a component of maturation promoting factor (MPF) and appears in higher eukarocytes to primarily control mitotic events (reviewed in Hunt, 1989) . Through complementation studies in yeast a second human cyclin dependent kinase was discovered, CDK2 (Elledge and Spottswood, 1991) . Although CDK2 can compliment a null mutation of cdc2 in yeast, the apparent role for CDK2 in humans is at the G 1 /S phase boundary Fang and Newport, 1991; Pagano et al., 1993; Rosenblatt et al., 1992; Tsai et al., 1993) .
The cyclins were ®rst identi®ed in invertebrate embryos as proteins whose concentration¯uctuated during the cell cycle (Hunt, 1989) . The cyclins identi®ed so far fall into three families, the G 1 cyclins (D1, D2, D3 and E), the S phase cyclin A and the G 2 / M cyclin B, (Sherr, 1993) . Cyclin A/CDK1 also contains an MPF-like activity, arguing that cyclin A has roles in both S phase and a cyclin B-like role in G 2 / M (Sherr, 1993; Pines, 1993) . Cyclin B has been shown to contain a nuclear localization signal near the amino terminus that is lacking in cyclins A and E (Pines and Hunter, 1994) .
All classes of cyclins share a limited homology in a region termed the cyclin box which, for cyclin A, has been shown to be required to bind the kinase (Hunt, 1991; Kobayashi et al., 1992; Lees and Harlow, 1993) . However, the binding of cyclin to kinase may not appear to be sucient for activation of the kinase (Ducommun et al., 1991) . Cyclins A and E retain the highest identity of all cyclin members throughout their cyclin box domains (Hunt, 1991; Nugent et al., 1991) . The two cyclin proteins have been shown to bind to both CDK1 and CDK2 (Ko et al., 1991; Pines, 1993; Rosenblatt et al., 1992; Roy et al., 1991) . Peaks in protein levels and associated kinase activities of cyclins A and E overlap signi®cantly through late G 1 and early S phase Ko et al., 1991 Ko et al., , 1992 Pines, 1993) . Microinjection of either cyclin A or cyclin E mRNA, or overexpression of either protein, causes premature entry into S phase (Girard et al., 1991; Quelle et al., 1993; Resnitzky et al., 1994 Resnitzky et al., , 1995 . Both cyclin/kinase complexes phosphorylate histone H1 and the retinoblastoma susceptibility gene product (pRb) in vitro, although the E/CDK1 complex only weakly phosphorylates histone H1 (Hinds et al., 1992; Horton et al., 1995; Ko et al., 1992; Pines and Hunter, 1991) .
Despite similar binding partners, overlapping expression and the ability to promote S phase entry there are important dierences in the abilities of cyclins A and E to activate kinase and recognize substrate. Corresponding to the G 2 expression of cyclin A, it forms a highly active complex with CDK1, whereas cyclin E only minimally activates CDK1 (Ko et al., 1991) . Cyclin A/CDK complexes are more active in phosphorylating an S phase substrate DP-1 than cyclin E/CDK (Dynlacht et al., 1994) . More recently the tumor suppressor p53 has been shown to be a substrate of cyclin A/CDK2 but not E/ CDK2 (Wang and Prives, 1995) .
We show here that lamin B is phosphorylated by cyclin A/CDK and is not recognized by cyclin E/CDK in vitro. Additionally, cyclin A, but not cyclin E, activates CDK1. We constructed a panel of chimeric proteins between the two cyclins, using regions of identity to interchange major domains of each of the cyclin proteins. Each of the cyclins are dependent on native cyclin box and C terminal domains to bind and activate CDKs. Despite the functional similarities of cyclins A and E, disruption of their native C terminal domains (including the cyclin box and C-termini) results in inability to bind kinase. N-terminal domain swaps between the cyclins yielded no change in substrate recognition or kinase activation compared to wild type cyclin proteins. Therefore we ascribe the lamin B substrate recognition and kinase activation of the cyclin/CDK complex to the cyclin box-C-terminus of the protein.
Results

Construction of cyclin A and E chimeras
Cyclins A and E are highly homologous in their cyclin box domains but show limited homology outside of the cyclin box (Hunt, 1991) . Since cyclins A and E are thought to bind CDK1 and CDK2 through their cyclin boxes, but dier in kinase activities toward E2F/DP-1, p53 and lamin B, we hypothesized that cyclins target CDKs to speci®c substrates via sequences either in the N-terminal or C-terminal domains of the cyclin molecules. To determine domains on cyclins A and E that are essential for kinase binding, activation and substrate targeting we constructed chimeric proteins between cyclins A and E. The fusion sites and resultant chimeric proteins are shown in Figure 1 . We used epitope tagged versions of these chimeras so that all could be analysed with the same monoclonal antibody (termed anti-EE) and protein levels on Western blots could be directly compared.
Chimeras were tested for ability to bind CDK2 and for histone H1 kinase activity. Results are summarized in Figure 1 . The AEE chimera made at the 184/111 fusion site and the EAA chimera made at the 100/174 fusion site were functional in binding CDK and phosphorylating histone (Figure 1 , see also Figures  3a and 4a) . Chimeras exchanging the C terminus of the cyclins and those exchanging the cyclin boxes were all non-functional in binding CDK and phosphorylating histone H1 (data not shown). We cannot exclude trivial explanations such as aberrant protein folding and destruction of three dimensional structure for the lack of activity of the non-functional chimeras.
Lamin B is phosphorylated by cyclin A but not cyclin E In a search for cyclin/kinase speci®c substrates we tested lamin B, a known substrate of cyclin B/CDK1. We compared the ability of cyclin B/CDK1, cyclin A/ CDK2 and cyclin E/CDK2 to phosphorylate lamin B (Figure 2 ). In addition to phosphorylation by cyclin B/ CDK1, lamin B is phosphorylated by CDK2 in conjunction with cyclin A (Figure 2 and see also Figure 3b ). However, the cyclin E/CDK2 kinase complex is unable to phosphorylate lamin B. The timing of lamin B phosphorylation within the cell cycle correlates with the timing of the cyclin A/CDK1 complex, rather than the cyclin A/CDK2 complex. Thus, it is likely that cyclin A/CDK1, along with cyclin B/CDK1, may be the physiological lamin B kinase complex. Moreover, this result identi®es a new substrate speci®c for cyclin A.
The cyclin box and cyclin C-terminus determines substrate speci®city
We next tested whether the N terminus or the cyclin box/C terminus of the cyclins was necessary for substrate speci®city in conjunction with the CDK2 kinase. In our initial studies we found that cyclins A and E phosphorylated histone H1 equally. To control for variability in separate kinase preparations we tested each of the cyclin/CDK preparations on histone H1. For each experiment we pre-tested each preparation of histone H1 phosphorylation and used equivalent H1-phosphorylation units when testing the cyclin/kinases on GST-pRb-large pocket (GST-Rb-LP) and bacte- Figure 1 Schematic diagram depicting the construction of chimeric cyclin genes and the resulting chimeric cyclin proteins. Points of fusion are represented by the amino acid number of cyclins A and E. Cyclin A is represented by a thin line and cyclin E by a thick line. Location of the cyclin box is shown over cyclin A and cyclin E. Kinase binding and histone H1 activity measured for each of the constructed chimeras is shown in a panel to the right of the diagrams. All chimeras diagrammed were expressed successfully, but most lacked kinase binding and H1 kinase activity. Only cyclin chimeras AEE (184/ 111) and EAA (100/174) retained activity; these chimeras are described in further experiments.`AEE' refers to the molecule containing the Amino terminus of cyclin E, and the cyclin box and C-terminus of cyclin E (amino acid junctions denoted above).`EAA' refers to the opposite molecule, with only the amino terminus of cyclin E
Kinase: Cyclin: ATP. CDK's in this study do not contain the epitope tag, and purify on the basis of their association with epitope tagged cyclin. Cyclin A/ CDK2 and cyclin B/CDK1 both phosphorylate lamin B dependent on the presence of kinase, whereas cyclin E/CDK2 is unable to phosphorylate lamin B. Exposure time was 3 h rially produced lamin B substrates (see Materials and methods). The bacterial lamin B, recognized by a monoclonal lamin B antibody, migrated as a doublet and both bands were quanti®ed together ( Figure 3b and data not shown). Cyclins A/CDK2 and E/CDK2 phosphorylated both GST-Rb-LP ( Figure 3c ) and lamin B (Figure 3b ) dierentially despite their equivalent kinase activities towards histone H1. Phosphorylation of pRb by cyclin E/CDK2 was about 40% that of cyclin A/CDK2, while phosphorylation of lamin B by cyclin E/CDK2 was essentially nil. Using the cyclin chimeras we determined the region of the cyclin which confers substrate speci®city.
Cyclins A/CDK2 and EAA/CDK2 both phosphorylated lamin B with equal eciency, while cyclins E/ CDK2 and AEE/CDK2 respectively phosphorylated lamin B at least sixfold less eciently. A similar result was obtained using lamin B isolated from nuclear envelopes (see Figure 2 and data not shown). GST-Rb-LP was also dierentially phosphorylated by the cyclin/ CDKs and followed the pattern seen with the lamin B substrate (Figure 3b ). Like cyclin A/CDK2, cyclin EAA/ CDK2 showed a higher kinase activity towards pRb than did cyclin E/CDK2 or AEE/CDK2 (Figure 3c , lane 5).
Immunoblotting con®rmed equivalent recoveries of cyclins E, AEE and EAA from experiments in which the cyclins were co-expressed with CDK2 ( Figure 3d ). Cyclin A recovery was reduced compared to the recovery of the other cyclins. However all cyclins eciently co-immunoprecipitated the co-expressed CDK2 ( Figure 3d ). Although the levels of cyclin expression varied, the ratio of cyclin to kinase was the same for all cyclin/kinase preparations. In time course experiments (not shown), phosphorylation of Histone H1 by each of the cyclin/CDK2 combinations proceeded linearly and equivalently for 10 min, while cyclin E/CDK2 and cyclin AEE/CDK2 complexes phosphorylated lamin B at only one-sixth the rate of A/CDK2 and EAA/CDK2.
Speci®c requirement for cyclin A C-terminus for CDK1 activation
While both cyclin A and cyclin E can activate CDK2, we found that cyclin E is unable to cooperate with CDK1 (i.e. cdc2). The reaction of cyclins A, E, AEE and EAA together with CDK1 in an in vitro kinase assay is shown using histone H1 (Figure 4a again reduced compared to the recovery of the other cyclins, as is the co-immunoprecipitated CDK1 ( Figure  4d ). Although the levels of cyclin expression varied, the ratio of cyclin to kinase was again the same for all cyclin/ kinase preparations.
Thus, cyclin A/CDK1 and cyclin EAA/CDK1 complexes eciently phosphorylate histone H1, while the cyclin E/CDK1 and AEE/CDK1 complexes lack signi®cant kinase activity towards histone H1. Neither the N terminus of cyclin A nor the cyclin box/C terminus of cyclin E is sucient to activate CDK1 in our assay.
Binding of cyclin E retains binding to CDK1 even in the presence of CDK2
As shown above, cyclin E associates with CDK1, but this cyclin-kinase complex is inactive. The reason for the cyclin E/CDK1 inactivity is unclear. As a control to demonstrate that the non-productive binding of cyclin E to CDK1 was detected speci®cally, we again measured the binding of cyclins A and E to CDK1. We overexpressed CDK1 (without epitope tag) either alone or with epitope tagged cyclin A or cyclin E ( Figure 5) . In an additional experiment, we provided CDK2 by coexpression, to determine if CDK2 might easily displace the non-functional CDK1 from cyclin E. No CDK1 immunoreactivity is detected without transfection of the CDK1 expression plasmid (lane 2) since exogenously produced CDK1 is not recognized by the epitope tag antibody. Equal amounts of CDK1 is associated with both cyclins A and E (lanes 3 and 5), and the association of both cyclins A and E with CDK1 is only partially reversed by coexpression of CDK2 (lanes 4 and 6). Thus the relative anity of both cyclin A and E with CDK1 is roughly equivalent despite the inability of cyclin E/CDK1 to form an active kinase in this system. The inactivity of cyclin E/CDK1 complexes is not due to tyrosine phosphorylation of CDK1 Despite the ability of cyclin E and cyclin AEE to bind CDK1 kinase, these complexes do not form active kinase complexes. Cyclin/kinase complexes can be inhibited by phosphorylation of a conserved tyrosine residue (amino acid 15 in CDK1 and CDK2), within the ATP binding domain of the kinase, and this can be reserved by the cdc25 phosphatase (Solomon, 1993) . The inactive cyclin E/CDK1 complex may be inactive because it is inhibited by quantitative phosphorylation within the ATP binding domain possibly because cyclin E/CDK1 fails to recruit the necessary phosphatase to dephosphorylate this residue. However, CDK1 coimmunoprecipitated with cyclin E demonstrated undetectable levels of phosphotyrosine, shown by both anti-phosphotyrosine immunoblot and phosphoamino analysis of 32 P-labeled proteins (data not shown). In addition treatment of the cyclin/kinase complex with a tyrosine speci®c phosphatase, PTP1B did not increase cyclin E/CDK1 or cyclin AEE/CDK1 activity towards histone H1 (Figure 6 , lanes 5, 6, 7 and 8). In contrast to the lack of eect on cyclins E and AEE, cyclin A/ CDK1 and EAA/CDK1 activity towards histone H1 increased after treatment with PTP1B, ostensibly because a fraction of the CDK1 contains the inhibitory tyrosine phosphorylation (Figure 6 , lanes 3 and 4, 9 and 10). We conclude that the absence of cyclin E/CDK1 activity in vitro is not due to an inhibitory tyrosine phosphorylation on CDK1.
Discussion
Cyclin A and cyclin E dier in their ability to form a functional kinase complex with CDK1 and CDK2. The ability to activate CDK1 is speci®c to cyclin A and demonstrates that the activation of all CDKs is dependent upon more than simple cyclin association. One such possibility is that the cyclins may act to recruit necessary activating factors, as is the case with cyclin B and cdc25 (Solomon, 1993) . We have shown that dephosphorylation of the inactive CDK1/cyclin E complex with PTP1B is unable to restore activity. Thus, phosphorylation of CDK1 phosphorylation on tyrosine 15 is unlikely to be the mechanism that prevents cyclin E/CDK1 complexes. Recent studies have shown that the cyclin E/CDK1 complex can be phosphorylated by the CDK activating CAK kinase on threonine 161 of CDK1, but that this is insucient for activation of the kinase (Desai et al., 1995) . This result is compatible with our ®ndings.
Analysis of our cyclin chimeras has partially localized the ability to activate speci®c kinases to a portion of the cyclin molecule. The chimeric cyclins retained the ability to activate CDK1 in every instance that the cyclin box and C-terminus of cyclin A was preserved. Likewise those chimeras with the cyclin box and C-terminus of cyclin E could activate CDK2, but not CDK1. Therefore these domains function to provide the speci®c activation of the bound CDK, while the amino terminus of the cyclin must contribute uncharacterized properties. This is in close agreement to previous ®ndings in which the amino terminal domains of cyclin A were unnecessary for CDK binding and activation of histone H1 kinase activity (Kobayashi et al., 1992; Lees and Harlow, 1993) . Many other chimeric cyclin molecules were prepared that segregated dierent segments of the cyclin molecules. Despite construction of the fusion proteins based on areas of high homology, none but those with intact cyclin box and C-termini retained the ability to bind and activate kinase. We conclude that precise structural conformation of the cyclins must be important for retention of the ability to bind and activate kinase.
We have identi®ed lamin B as substrate speci®c for cyclin A. Despite equivalent histone H1 kinase activities of both cyclins A/CDK2 and E/CDK2, cyclin E/CDK2 complexes are unable to phosphorylate lamin B. The speci®city of cyclin A/CDK for lamin B is in concert with the model that phosphorylation of lamin B by CDK is an event required for nuclear envelope breakdown preceding mitosis (McKeon, 1991) . Since cyclin A/CDK activity extends Histone H1<
Cyclin/Kinase: PTP1B: Figure 6 Treatment with a tyrosine phosphatase enhances the histone H1 kinase activity of cyclin A/CDK1 and cyclin EAA/ CDK1 but not cyclin E/CDK1 or AEE/CDK1. Immunopuri®ed cyclin/CDK1 was treated with either kinase buer alone (odd numbered lanes) or with PTP1B (even numbered lanes) for 30 min. Phosphatase reactions were stopped by addition of 1 mM sodium orthovanadate and 10 mM PNPP. In vitro histone H1 kinase assays of treated and untreated samples were then performed by addition of 0.5 mg of H1 and 10 mCi [g 32 P]ATP. Samples were analysed using 12.5% SDS ± PAGE well into G 2 , this temporal peak of activity coincides with the anticipated timing of nuclear envelope protein phosphorylation. It might be expected that should G 1 cyclins phosphorylate lamin B, the cell might undergo premature mitotic events, such as the premature chromatin condensation associated with mutation of the RCC1 gene (Uchida et al., 1990) .
Similar to the ability of the cyclin box and Cterminus of cyclins to specify CDK utilization, analysis of our cyclin chimeras demonstrated that the cyclin box and C-terminus of cyclin A provides the speci®city of substrate recognition to CDK2. The fact that it is the cyclin moiety of the cyclin/CDK complex that identi®es substrate rather than the CDK itself is in con¯ict with the generally accepted model for substrate binding by kinases. The crystallographic structures of CDK2 (De-Bondt et al., 1993; Jerey et al., 1995) , MAP kinase (Zhang et al., 1993) and PKA , have shown that these kinases are similar in containing a polypeptide loop that obstructs access to the substrate binding domain. These and many other kinases are activated at least in part by phosphorylation of residues within these domains (e.g. thr 160 on CDK2, and thr 183 and tyr 185 on MAP kinase) which can be seen as altering the conformation of the loop to provide access (Marshall, 1994; Taylor et al., 1993) . If this model is accurate, the recognition of speci®c substrates by dierent kinases should lie within the realm of the kinase.
Binding of CDK's by cyclins oers an additional level of control over the operation of the activation loop and the substrate binding pocket, as shown by the recent crystal structure of CDK2 bound to a fragment of cyclin A (Jerey et al., 1995) . This structure has revealed that cyclin A binding folds open the activation loop to two eects: ®rst, to allow access to substrate (and approximation of the substrate to the g-phosphate of the bound ATP), and second to shift the thr 160 within the loop to the surface where it can be phosphorylated by CAK, presumably opening the substrate binding pocket further.
Our data provides functional con®rmation of some of the predictions made by the crystal structure, in the binding of the cyclin box and C-terminus of the cyclin (similar to the cyclin fragment co-crystallized with CDK) speci®es the nature of the substrate recognized by the CDK-cyclin complex. Binding of speci®c cyclins must result in conformations that allow highly speci®c substrate recognition beyond the level provided by the basic CDK consensus phosphorylation motif (P-S/T-Xbasic). While all cyclin-CDK2 molecules recognize this core motif (as re¯ected by the shared ability to phosphorylate histone H1 and pRb), only the precise conformation aorded by cyclin A binding allows the higher level of speci®city required to recognize lamin B as substrate. If substrates speci®c to cyclin E/CDK complexes exist, they have yet to be identi®ed.
We have, through the use of chimeric proteins, de®ned a role for the cyclin box and C-terminus of the cyclin protein. That role is to target speci®city of both CDK activation and substrate recognition. We have also de®ned a new cyclin A/CDK speci®c substrate, lamin B, and have clari®ed the mechanism by which kinase recognizes substrate. Through further study of individual cyclin/CDK complexes and by further elucidation of cyclin speci®c CDK substrates we will gain a better understanding of the unique role each cyclin/CDK plays in promoting cell cycle progression.
Materials and methods
Cell culture
CV1 cells were maintained in high-glucose DMEM supplemented with 10% bovine calf serum and antibiotics.
Plasmids
Construction of the CDK1-TM1, CDK2-TM1, cyclin A-5'EE TM1, cyclin E-5'EE TM1 and pRb-5'HA TM1 as described elsewhere (Horton et al., 1995) . A cDNA for lamin B was cloned into the pET bacterial expression vector (Novagen). Large pocket pRb-GST was a gift from Bill Kaelin (Dana Farber Cancer Institute, Boston, MA). The chimeric cyclin mutants were created using site directed mutagenesis using a variation of the`mega primer mutagenesis' (Sarkar and Sommer, 1990) . In our variation primers containing the 5' sequence of one cyclin and 3' sequence of the opposing cyclin were made, encoding amino acid sequences common to both cyclins (see also Figure 1 ).`AEE' refers to the molecule containing the Amino terminus of cyclin E, and the cyclin box and Cterminus of cyclin E.`EAA' refers to the opposite molecule, with only the amino terminus of cyclin E.
Expression and isolation of proteins
We used the vaccinia virus/T7 polymerase expression system to express cyclins and kinases (Elroy-Stein et al., 1989; Moss et al., 1990) . While this system provides unnaturally high levels of protein expression, most posttranslational processes (e.g. phosphorylation and nuclear translocation) proceed at apparently normal levels (Horton et al., 1995; Qian et al., 1992; Templeton, 1992) . Approximately 2610 7 CV1 cells were starved 24 h before infection in 0.2% calf serum, then infected with vaccinia virus vector vTF7-3 (Moss et al., 1990) encoding the phage T7 RNA polymerase and lipofected (Rose et al., 1991) using 10 mg of pTM1 expression plasmids. For cotransfections of cyclins and kinase 10 mg of each plasmid was used. Twenty-four hours after transfection cultures were lysed in MLB (25 mM morpholinepropanesulfonic acid, (pH 7.0), 250 mM NaCl, 5 mM EDTA, 0.1% NP40. 1 mM DTT (dithiothreitol), 1 mg/ml aprotinin, 1 mg/ml leupeptin and 50 mg/ml phenylmethylsulfonyl¯uoride) and clari®ed by centrifugation. Epitope tagged proteins were immunoprecipitated using EE antibody conjugated to agarose beads (5 mg EE antibody/ml of Agel 10 (BRL, Gaithersberg, Maryland);`anti-EE beads'). Samples were washed MLB, once in 50 mM Tris (pH 7.4) ± 1 mM DTT (TD) and eluted into 50 ml TD containing 0.1 mg/ml of the peptide cognate to the EE antibody (EEEEYMPME) and 20% glycerol. pRb substrate was isolated similarly, omitting serum starvation and using immunoprecipitation with 12CA5 (anti HA) antibody for HA-tagged pRb. Lamin B was isolated from rat liver nuclear envelopes using a procedure outlined previously (Templeton et al., 1991) .
Epitope tagged cyclin molecules were employed throughout the work, while kinase molecules were untagged. While potential alterations in conformation are possible in modi®ed proteins, known activities of the cyclins/CDKs mirror the known properties of proteins monitored elsewhere. Additionally, the epitope tag approach aords the possibility of measuring enzyme activity without bound antibody, which may sterically alter activity.
For substrate isolated from bacteria either pRb-GST or lamin B 5'EE pET were expressed in BL21 bacteria. Lamin B 5'EE pET was isolated according to the pET system manual from Novagen except that the cultures were induced with IPTG overnight. GST-Rb-LP was isolated as previously described (Ewen et al., 1993) .
In vitro kinase assays
For assays with cyclin/CDK1, 2 ml each of the cyclins was mixed with 8 ml pRb protein A slurry or with 0.5 mg/ml histone H1 (Sigma, St. Louis, MO) or with 4 ml nuclear envelopes in a ®nal reaction mixture of 20 ml containing TD, 10 mM MgCl 2 , and 10 mCi of [g-32 P]ATP (6000 Ci/ mmol) per reaction. Samples were run on 12.5% SDS ± PAGE, transferred to Immobilon-P ®lters (Millipore, Bedford, MA) and analysed by autoradiography and AMBIS quanti®cation. For assays using cyclin/CDK2, 2 ml of each of the cyclins was mixed with 0.5 mg/ml histone H1 in a ®nal reaction mixture of 20 ml as described above. For all further in vitro kinase assays equivalent amounts of cyclin/CDK2 histone kinase activities (as measured by AMBIS) were used to normalize reactions. Dilutions of the cyclin/kinases made to achieve equivalent histone kinase activities are as follows: Cyclin A-no dilution, cyclin E-1.5 dilution, cyclin AEE-no dilution, cyclin EAA-2.0 dilution. 2 ml of each of these dilutions were mixed with 0.5 mg/ml histone H1 or 0.5 mg/ml pRb-large pocket-GST or 0.05 mg/ml lamin B in a ®nal reaction mixture of 20 ml as described above. In vitro kinase time course assays using the cyclin/CDK1 complexes were performed as above using 0.5 mg/ml histone H1 sampling at 30 s, 1 min, 2 min, 5 min and 10 min after radiolabel addition. In vitro kinase time course assays using the cyclin/CDK2 complexes were performed as above using either 0.5 mg/ml pRb-LP-GST or 0.05 mg/ml lamin B-5'EE sampling at 1 min, 2 min, 5 min, 10 min and 30 min or 0.5 mg/ml histone H1, sampling as above.
Western blot analysis
Radioactive samples transferred to Immobilon-P were subjected to immunoblot analysis. After quanti®cation by AMBIS, HA-tagged pRb were detected with 12CA5 ascites (anti HA). To con®rm cyclin expression and kinase binding, 10 ml of the original 50 ml cyclin/kinase eluate was run on a 12.5% SDS ± PAGE and transferred to Immobilon-P. The cyclins were detected using anti-EE ascites, CDK1 was detected using a monoclonal antibody to CDK1 (Cell Biology Products, GIBCO-BRL, Gaithersberg, MD) and CDK2 was detected using a polyclonal antibody against CDK2 (Upstate Biotechnology Incorporated, Lake Placid, NY).
CDK1 co-immunoprecipitation
CV1 cells were infected/transfected as above with 5 mg plasmid DNA encoding untagged CDK1, CDK1 plus cyclin A or cyclin E, or CDK1 plus CDK2 and cyclin A or cyclin E. Twenty-four hours after lipofection cells were lysed in MLB as above. Lysates were clari®ed by centrifugation and 1% of the lysate removed to con®rm equivalent expression of CDK1 resulting from all transfection. The tagged proteins were immunoprecipitated using anti-EE beads as above. Samples were washed four times in 16MLB, once in 50 mM Tris (pH 7.4) ± 1 mM DTT (TD) and the proteins were eluted into 50 ml TD containing 0.1 mg/ml of the peptide cognate to the EE antibody (EEEEYMPME). Samples were then run on 12.5% SDS ± PAGE, and after electrophoresis transferred to Immobilon-P ®lters (Millipore). The presence of co-immunoprecipitated CDK1 was visualized using a monoclonal antibody to CDK1 (Cell Biology Products, GIBCO-BRL, Gaithersberg, MD).
Phosphatase treatment CDK1 kinase isolated as described above was treated for 30 min in kinase buer either with or without 25 000 units of bacterially produced PTPB1 (a gift of Gary Landreth, CWRU) at room temperature. After the 30 min incubation 1 mM sodium vanadate, 10 mM PNPP, 10 mCi [g 32 -P]ATP and 0.5 mg/ml histone H1 were added to each reaction and incubated for 10 min at room temperature. Samples were run and analysed on 12.5% SDS ± PAGE and autoradiography.
